Benign Prostatic Hyperplasia Treatment Global Market Report 2025

Description

Benign prostatic hyperplasia (BPH) treatment encompasses medical, minimally invasive, and surgical approaches aimed at managing symptoms of an enlarged prostate. BPH is a common condition among aging men, often causing urinary problems such as frequent urination, weak stream, and incomplete bladder emptying.

The primary treatment options for BPH include minimally invasive surgery (MIS) and invasive surgery. Minimally invasive surgery (MIS) utilizes small incisions, specialized instruments, and advanced imaging technology to perform procedures with minimal trauma. The therapeutic classes for BPH treatment consist of alpha blockers, 5-alpha reductase inhibitors, phosphodiesterase-5 inhibitors, and other therapeutic categories. These treatments serve various end users, including home healthcare, hospitals and clinics, as well as research and manufacturing facilities.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The benign prostatic hyperplasia treatment market research report is one of a series of new reports from The Business Research Company that provides benign prostatic hyperplasia treatment market statistics, including the benign prostatic hyperplasia treatment industry's global market size, regional shares, competitors with a benign prostatic hyperplasia treatment market share, detailed benign prostatic hyperplasia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the benign prostatic hyperplasia treatment industry. This benign prostatic hyperplasia (BPH) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The benign prostatic hyperplasia treatment market size has grown strongly in recent years. It will grow from $8.23 billion in 2024 to $8.69 billion in 2025 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to growing awareness and screening initiatives, rising prevalence of BPH, increasing healthcare awareness, improving healthcare infrastructure, and growing elderly population.

The benign prostatic hyperplasia treatment market size is expected to see strong growth in the next few years. It will grow to $10.74 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to the rising adoption of minimally invasive procedures, a growing number of geriatric patients, a rising availability of advanced treatment options, a growing focus on patient-centric care, and a rising prevalence of comorbidities. Major trends in the forecast period include developing targeted therapies, integration of digital health solutions, innovation in surgical options, integration of 3D imaging for diagnosis, and innovation in patient-centered care models.

The forecast of 5.5% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. urology by inflating prices of laser prostatectomy systems and alpha-blocker medications developed in Germany and India, resulting in prolonged urinary symptoms and higher surgical intervention costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing adoption of minimally invasive surgeries is expected to drive the growth of the benign prostatic hyperplasia (BPH) treatment market. These procedures involve small or no incisions, using specialized instruments to minimize recovery time, pain, and the risk of complications. The growing preference for minimally invasive surgeries is attributed to benefits such as shorter recovery times, reduced pain, lower risk of complications, and improved cosmetic outcomes. BPH treatment through minimally invasive procedures offers patients effective symptom relief with fewer complications and faster recovery. For example, in September 2023, the American Society of Plastic Surgeons (ASPS), a US-based professional association, reported that 23,672,269 cosmetic minimally invasive procedures were performed globally in 2022, including treatments such as neuromodulator injections, lip augmentation, and non-invasive skin tightening. Consequently, the increasing adoption of minimally invasive surgeries is fueling the growth of the BPH treatment market.

Leading companies in the BPH treatment market are focusing on innovative solutions, particularly minimally invasive procedures, to improve patient outcomes and reduce recovery times. These techniques involve minimal or no incisions, reducing trauma, pain, and complications while ensuring faster recovery compared to traditional surgical methods. For instance, in December 2022, Teleflex Incorporated, a US-based medical device company, introduced the UroLift System for BPH treatment. This system uses small permanent implants to reposition enlarged prostate tissue, providing significant symptom relief without requiring tissue removal, cutting, or heating. As an outpatient treatment, it allows for rapid recovery, preserves sexual function, and delivers superior symptom relief compared to conventional BPH medications, with side effects typically resolving within two to four weeks.

In October 2023, Laborie Medical Technologies, Inc., a US-based medical technology company, acquired Urotronic for $600 million. This acquisition aims to expand Laborie's interventional urology portfolio, enhance its technological capabilities, and strengthen its global presence in minimally invasive urological treatments. Urotronic, Inc., a US-based medical device company, specializes in developing and marketing minimally invasive treatments for BPH.

Major players in the benign prostatic hyperplasia treatment market are Pfizer Inc., Merck And Co Inc, AbbVie Inc., Bayer AG, Sanofi S.A., GlaxoSmithKline Public Limited Company, Medtronic Public Limited Company, Mezzion Pharma Co Ltd, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Boston Scientific Corporation, Astellas Pharma Inc., Olympus Corporation, Coloplast Group, Teleflex Incorporated, Cook Medical Incorporated, AngioDynamics, Inc., HistoSonics Inc, Urovant Sciences Ltd, UroGen Pharma Ltd., Urologix Inc, Zenflow Inc, and Butterfly Medical Ltd.

North America was the largest region in the benign prostatic hyperplasia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in benign prostatic hyperplasia treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the benign prostatic hyperplasia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The benign prostatic hyperplasia treatment market consists of revenues earned by entities by providing services such as pharmacological treatments, minimally invasive procedures, surgical treatments, diagnostic services, and prostatic stents. The market value includes the value of related goods sold by the service provider or included within the service offering. The benign prostatic hyperplasia treatment market also includes sales of transurethral microwave thermotherapy, prostatic urethral lift, acupuncture, combination therapy, phosphodiesterase-5 inhibitors, and minimally invasive devices. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Benign Prostatic Hyperplasia Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on benign prostatic hyperplasia treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for benign prostatic hyperplasia treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The benign prostatic hyperplasia treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Treatment: Minimal Invasive Surgery; Invasive Surgery
2) By Therapeutic Class: Alpha Blockers; 5-Alpha Reductase Inhibitors; Phosphodiesterase-5 Inhibitors; Other Therapeutic classes
3) By End User: Home Healthcare; Hospitals And Clinics; Research And Manufacturing
Subsegments:
1) By Minimal Invasive Surgery: Transurethral Resection of the Prostate (TURP); Laser Surgery; Prostatic Urethral Lift; Transurethral Incision of the Prostate (TUIP); Microwave Therapy
2) By Invasive Surgery: Open Prostatectomy; Robotic Prostatectomy
Companies Mentioned: Pfizer Inc.; Merck And Co Inc; AbbVie Inc.; Bayer AG; Sanofi S.A.; GlaxoSmithKline Public Limited Company; Medtronic Public Limited Company; Mezzion Pharma Co Ltd; Eli Lilly and Company; Teva Pharmaceutical Industries Ltd.; Boehringer Ingelheim; Boston Scientific Corporation; Astellas Pharma Inc.; Olympus Corporation; Coloplast Group; Teleflex Incorporated; Cook Medical Incorporated; AngioDynamics, Inc.; HistoSonics Inc; Urovant Sciences Ltd; UroGen Pharma Ltd.; Urologix Inc; Zenflow Inc; Butterfly Medical Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r33978u

1. Executive Summary

2. Benign Prostatic Hyperplasia Treatment Market Characteristics

3. Benign Prostatic Hyperplasia Treatment Market Trends And Strategies

4. Benign Prostatic Hyperplasia Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Benign Prostatic Hyperplasia Treatment Growth Analysis And Strategic Analysis Framework

5.1. Global Benign Prostatic Hyperplasia Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Benign Prostatic Hyperplasia Treatment Market Growth Rate Analysis
5.4. Global Benign Prostatic Hyperplasia Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Benign Prostatic Hyperplasia Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Benign Prostatic Hyperplasia Treatment Total Addressable Market (TAM)

6. Benign Prostatic Hyperplasia Treatment Market Segmentation

6.1. Global Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Minimal Invasive Surgery
Invasive Surgery
6.2. Global Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Alpha Blockers
5-Alpha Reductase Inhibitors
Phosphodiesterase-5 Inhibitors
Other Therapeutic classes
6.3. Global Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Home Healthcare
Hospitals And Clinics
Research And Manufacturing
6.4. Global Benign Prostatic Hyperplasia Treatment Market, Sub-Segmentation Of Minimal Invasive Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Transurethral Resection of the Prostate (TURP)
Laser Surgery
Prostatic Urethral Lift
Transurethral Incision of the Prostate (TUIP)
Microwave Therapy
6.5. Global Benign Prostatic Hyperplasia Treatment Market, Sub-Segmentation Of Invasive Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Open Prostatectomy
Robotic Prostatectomy

7. Benign Prostatic Hyperplasia Treatment Market Regional And Country Analysis

7.1. Global Benign Prostatic Hyperplasia Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Benign Prostatic Hyperplasia Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market

8.1. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Benign Prostatic Hyperplasia Treatment Market

9.1. China Benign Prostatic Hyperplasia Treatment Market Overview
9.2. China Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Benign Prostatic Hyperplasia Treatment Market

10.1. India Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Benign Prostatic Hyperplasia Treatment Market

11.1. Japan Benign Prostatic Hyperplasia Treatment Market Overview
11.2. Japan Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Benign Prostatic Hyperplasia Treatment Market

12.1. Australia Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Benign Prostatic Hyperplasia Treatment Market

13.1. Indonesia Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Benign Prostatic Hyperplasia Treatment Market

14.1. South Korea Benign Prostatic Hyperplasia Treatment Market Overview
14.2. South Korea Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Benign Prostatic Hyperplasia Treatment Market

15.1. Western Europe Benign Prostatic Hyperplasia Treatment Market Overview
15.2. Western Europe Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Benign Prostatic Hyperplasia Treatment Market

16.1. UK Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Benign Prostatic Hyperplasia Treatment Market

17.1. Germany Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Benign Prostatic Hyperplasia Treatment Market

18.1. France Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Benign Prostatic Hyperplasia Treatment Market

19.1. Italy Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Benign Prostatic Hyperplasia Treatment Market

20.1. Spain Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Benign Prostatic Hyperplasia Treatment Market

21.1. Eastern Europe Benign Prostatic Hyperplasia Treatment Market Overview
21.2. Eastern Europe Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Benign Prostatic Hyperplasia Treatment Market

22.1. Russia Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Benign Prostatic Hyperplasia Treatment Market

23.1. North America Benign Prostatic Hyperplasia Treatment Market Overview
23.2. North America Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Benign Prostatic Hyperplasia Treatment Market

24.1. USA Benign Prostatic Hyperplasia Treatment Market Overview
24.2. USA Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Benign Prostatic Hyperplasia Treatment Market

25.1. Canada Benign Prostatic Hyperplasia Treatment Market Overview
25.2. Canada Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Benign Prostatic Hyperplasia Treatment Market

26.1. South America Benign Prostatic Hyperplasia Treatment Market Overview
26.2. South America Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Benign Prostatic Hyperplasia Treatment Market

27.1. Brazil Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Benign Prostatic Hyperplasia Treatment Market

28.1. Middle East Benign Prostatic Hyperplasia Treatment Market Overview
28.2. Middle East Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Benign Prostatic Hyperplasia Treatment Market

29.1. Africa Benign Prostatic Hyperplasia Treatment Market Overview
29.2. Africa Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Benign Prostatic Hyperplasia Treatment Market Competitive Landscape And Company Profiles

30.1. Benign Prostatic Hyperplasia Treatment Market Competitive Landscape
30.2. Benign Prostatic Hyperplasia Treatment Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Merck And Co Inc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Benign Prostatic Hyperplasia Treatment Market Other Major And Innovative Companies

31.1. GlaxoSmithKline Public Limited Company
31.2. Medtronic Public Limited Company
31.3. Mezzion Pharma Co Ltd
31.4. Eli Lilly and Company
31.5. Teva Pharmaceutical Industries Ltd.
31.6. Boehringer Ingelheim
31.7. Boston Scientific Corporation
31.8. Astellas Pharma Inc.
31.9. Olympus Corporation
31.10. Coloplast Group
31.11. Teleflex Incorporated
31.12. Cook Medical Incorporated
31.13. AngioDynamics, Inc.
31.14. HistoSonics Inc
31.15. Urovant Sciences Ltd

32. Global Benign Prostatic Hyperplasia Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Benign Prostatic Hyperplasia Treatment Market

34. Recent Developments In The Benign Prostatic Hyperplasia Treatment Market

35. Benign Prostatic Hyperplasia Treatment Market High Potential Countries, Segments and Strategies

35.1 Benign Prostatic Hyperplasia Treatment Market In 2029 - Countries Offering Most New Opportunities
35.2 Benign Prostatic Hyperplasia Treatment Market In 2029 - Segments Offering Most New Opportunities
35.3 Benign Prostatic Hyperplasia Treatment Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer